FDA Expands Indications for Echosens FibroScan Device

The FDA has expanded indications for Echosens’ FibroScan liver screening device to allow its use in more patients, including during pregnancy and for individuals with active implants.

FibroScan uses biomarkers to monitor patients over time for liver fibrosis and hepatic steatosis. It can also assess the likelihood of cirrhosis.

The patient population has been expanded from patients with liver disease to adult and pediatric patients with “confirmed or suspected” liver disease.